NASDAQ:TROV Cardiff Oncology (TROV) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.09▼$2.2850-Day Range$1.19▼$24.7152-Week Range$0.70▼$3.46Volume548,477 shsAverage Volume648,892 shsMarket Capitalization$23.23 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsTrendsStock AnalysisCompetitorsTrends Get Cardiff Oncology alerts: Email Address Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Cardiff Oncology Stock (NASDAQ:TROV)Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.Read More Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << TROV Stock News HeadlinesAugust 12, 2024 | seekingalpha.comCardiff: Second Half Of 2024 mCRC Data Is Major Inflection PointAugust 12, 2024 | msn.comCardiff Oncology, Inc. (NASDAQ:CRDF) Q2 2024 Earnings Call TranscriptSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 9, 2024 | markets.businessinsider.comCRDF Stock Earnings: Cardiff Oncology Misses EPS, Beats Revenue for Q2 2024August 9, 2024 | markets.businessinsider.comCardiff Oncology Reports Second Quarter 2024 Results and Provides Business UpdateMay 22, 2024 | seekingalpha.comCardiff Oncology's Onvansertib: A Speculative Buy With Promising DataMay 7, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cardiff Oncology as Phase 2 Trial Shows Promise for Accelerated ApprovalFebruary 23, 2024 | benzinga.comCardiff Oncology Stock (NASDAQ:CRDF) Dividends: History, Yield and DatesSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.September 29, 2023 | markets.businessinsider.comCardiff Oncology’s Onvansertib Shows Promise: An Analysis of the Buy Rating RecommendationSeptember 26, 2023 | marketwatch.comStocks to Watch: MillerKnoll, Cardiff Oncology, Morphic HoldingsAugust 8, 2023 | marketwatch.comCardiff Oncology Shares Up 26% After Potential Cancer Treatment AdvancesAugust 8, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Cardiff Oncology (CRDF)May 27, 2023 | fool.comCardiff Oncology (NASDAQ: CRDF)January 13, 2023 | forbes.comCardiff OncologyDecember 14, 2022 | seekingalpha.comCardiff Oncology: Staying The CourseOctober 16, 2022 | markets.businessinsider.comClear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively BuyingSeptember 29, 2022 | finance.yahoo.comCardiff Oncology, Inc. (CRDF)See More Headlines Receive TROV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2020Today9/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological Products, Except Diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TROV CUSIPN/A CIK1213037 Webwww.trovagene.com Phone(858) 952-7570FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,410,000.00 Net Margins-3,688.31% Pretax MarginN/A Return on Equity-202.00% Return on Assets-122.92% Debt Debt-to-Equity Ratio0.12 Current Ratio2.37 Quick Ratio2.37 Sales & Book Value Annual Sales$250,000.00 Price / Sales92.93 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book2.24Miscellaneous Outstanding Shares11,011,000Free FloatN/AMarket Cap$23.23 million OptionableNot Optionable Beta1.04 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMark ErlanderChief Executive Officer & DirectorVicki KelemenChief Operating Officer & Executive Vice PresidentBrigitte LindsaySecretary & Vice President-FinanceKey CompetitorsInvivydNASDAQ:IVVDElutiaNASDAQ:ELUTHilleVaxNASDAQ:HLVXInstil BioNASDAQ:TILBioAtlaNASDAQ:BCABView All Competitors TROV Stock Analysis - Frequently Asked Questions How were Cardiff Oncology's earnings last quarter? Cardiff Oncology, Inc. (NASDAQ:TROV) released its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. Cardiff Oncology had a negative net margin of 3,688.31% and a negative trailing twelve-month return on equity of 202.00%. When did Cardiff Oncology's stock split? Cardiff Oncology shares reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. What other stocks do shareholders of Cardiff Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY) and Alibaba Group (BABA). This page (NASDAQ:TROV) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiff Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.